Scienza e Tecnologia
IN3BIO gains approval for Phase I/II clinical trial
Erik D'Hondt, CEO of IN3BIO, said, "We are delighted to have reached this significant regulatory step to conduct our clinical trial in Bulgaria . This first approval will lead to patients being enrolled rapidly in centres in Bulgaria , then in clinical centres in other EU and non-EU countries."
IN01 vaccine is a proprietary biologic fusion molecule designed and developed by IN3BIO. It is administered after mixing with an adjuvant Montanide ISA 51 VG ST to produce an extemporaneous water in oil emulsion (W/O) known to enhance the immune response of therapeutic vaccines.
The vaccination of IN01 produces anti-EGF antibodies which capture EGF and prevent it from binding to its target, i.e. EGF-receptor on cell surface. This prevents proliferation of tumour cells affected by EGF mediated pathways.
IN01 is manufactured in a contracted certified GMP facility in the EU. Extensive testing as a single molecule or in combination with SMIs showed no adverse effect in several pre-clinical studies.
IN3BIO is a biotechnology company based in the UK and is dedicated to developing new therapeutics that can provide cancer patients with new and effective treatments with emphasis on tolerability. Established in 2010, it has built a broad R&D platform that offers potential treatment for multiple indications of cancer, both as mono therapy and in combination with other treatments. It has immuno-therapy programs in NSCLCL and a pipeline in other indications (head & neck, colorectal and breast cancer).